about
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in micePlatelet distribution width as the prognostic marker in coronary bifurcation treatment.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis.Statins impair glucose uptake in tumor cellsInhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.12-month intravascular ultrasound observations from BiOSS® first-in-man studiesProteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein responseMolecular mechanisms of the antitumor effects of anti-CD20 antibodies.Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.Bioresorbable vascular scaffolds-what does the future bring?BiOSS LIM C: thin-strut cobalt-chromium version of the dedicated bifurcation stent.The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review.Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicityAntitumor effects of the combination of cholesterol reducing drugs.Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application.Photodynamic therapy-driven induction of suicide cytosine deaminase gene.Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells.The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteinsProteolytic pathways involved in modulation of CD20 levels.First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C - 3-month results.Calcium-phosphate metabolism disturbances in patients with significant mitral regurgitation.Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.Assessment of vascular response to BiOSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model.Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience.Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.[The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk].Advances in mechanisms and treatment options of MINOCA caused by vasospasm or microcirculation dysfunction.Prediction of troponin elevation by means of intracoronary electrocardiogram during percutaneous coronary intervention of coronary bifurcation lesions (from COronary SIde Branch Residual IschemiA and COllateralization Assessment Study; COSIBRIA & CoFirst-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.Self-positioning properties of dedicated bifurcation coronary stent BiOSS LIM® in the eye of 3D optical coherence tomography.Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert® in the treatment of distal left main stem stenosis.Coronary spasm revascularized with a bioresorbable vascular scaffold.Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
P50
Q28472420-50319791-9D86-4029-B25F-4144C32FFBF8Q33351064-D34AD10F-0A97-4F32-9B5B-43AAB624D4AAQ33442212-EF64CDFB-3B04-4FE0-85C3-B4B56D45E84CQ33882390-924A6FFB-CAC3-4C7E-8D6D-13B72FC69E10Q35843028-ACBB6443-796E-4873-A4CE-CB1FB00FE88EQ35949773-5250490D-6A36-47A9-BD25-2F2DF2256BF5Q36213094-C56FC518-DCD4-42AD-9996-4D1AFD0A5518Q37344896-8F612728-C9CD-4AEF-B0E6-7ECB75BFD0E4Q37448609-ADCC072A-11F8-42A1-8886-41758BD27ECBQ37825142-866E5DD5-2D91-4147-94AC-3EA5CEE7A794Q38608665-838675B1-99D5-4646-8AD5-40FD73A84BF3Q38822091-688F07D6-0EA2-4882-832A-AB2286F21EDDQ38844452-0CE90964-4F47-487A-937B-E7C7FC3C3844Q38944947-2235CFC6-86F2-49BF-B25B-E6EFBB199433Q39306456-5450D668-352F-4D88-B3B2-A4620CE1201CQ39558955-2EF96B17-4D1F-4127-8BD2-5E59EF4AAEF1Q39612122-B2B74F5C-EA8C-43CD-99D8-F58A57BC5EEBQ39788382-655CBDF9-F3D3-49F2-BA01-A05AC1FED655Q39820701-CE96C9B2-62D3-46E4-A45F-DCEC2836DD7EQ40056305-087547A9-4321-49E5-A144-3AAFEDC2AAB1Q40094838-6131D599-CF5C-409C-984C-344989E3727DQ40135597-52049882-1A61-4F0E-900B-29995F844BC0Q42856089-8D358AB0-5819-48B9-BA65-EED2A313115CQ43007191-31F5D84D-3231-4B19-8DA0-B543E5A1EACEQ47296316-285B705F-DEB3-465E-A4E1-CEA28366B0EBQ47547810-66252C9E-F4DE-4A15-AD6C-250BE8FD3B10Q47891626-0BAB4E2A-B6E4-4C9F-AAEC-516E5DAC1CA6Q48257878-45385269-4AA4-4421-86F9-0753C9A5D9BCQ48719993-579CA221-541A-449C-BCCB-A96B9F50EF2FQ48794206-6C714197-19CE-4602-B334-4D1FAA04A46DQ48932983-F89C4AEF-7F03-49FB-B9D6-188CBCB78439Q50076133-D5990CB0-C854-47F8-BF21-3A23789ED6C1Q50141491-5C27673E-0452-4EE5-BF81-4E9EB2697AFAQ50905184-E99C2D3F-E7E5-41FF-9D72-F017F657CB6FQ51007425-D7D48D94-B22A-4A80-9F77-18327D6CB0BBQ51037923-4483C6DF-D464-4E8B-AE9D-FFB1B37859A2Q51632179-53963B96-F05A-4A16-BA37-36B65B4C2C9EQ51743381-812EA217-44F5-4C36-A271-0A4687F566E3Q51811438-CE2F40B2-03E2-4E25-8F18-BF8AD6BD4DACQ53276026-B1105918-8FEB-475E-AFE3-792A544F7F3F
P50
description
Pools onderzoeker
@nl
cercetător polonez
@ro
chercheur polonais
@fr
hulumtues
@sq
investigador polaco
@es
investigador polaco
@gl
investigador polacu
@ast
investigador polonès
@ca
polnischer Forscher
@de
polski naukowiec
@pl
name
Jacek Bil
@ast
Jacek Bil
@ca
Jacek Bil
@cs
Jacek Bil
@de
Jacek Bil
@en
Jacek Bil
@es
Jacek Bil
@fr
Jacek Bil
@ga
Jacek Bil
@gl
Jacek Bil
@hr
type
label
Jacek Bil
@ast
Jacek Bil
@ca
Jacek Bil
@cs
Jacek Bil
@de
Jacek Bil
@en
Jacek Bil
@es
Jacek Bil
@fr
Jacek Bil
@ga
Jacek Bil
@gl
Jacek Bil
@hr
prefLabel
Jacek Bil
@ast
Jacek Bil
@ca
Jacek Bil
@cs
Jacek Bil
@de
Jacek Bil
@en
Jacek Bil
@es
Jacek Bil
@fr
Jacek Bil
@ga
Jacek Bil
@gl
Jacek Bil
@hr
P214
P106
P1153
23987613600
P1412
P1559
Jacek Bil
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-8724-5611
P734
P735
P7859
viaf-315233121